Search Results
Aug 12, 2026, 09:44 ET Cohen & Steers Launches Real Assets Active ETF (CSRA)
NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced it has launched the Cohen & Steers Real Assets Active ETF (CSRA). This ETF harnesses the firm's four decades of leadership in listed
More news about: Cohen & Steers, Inc.
Aug 12, 2026, 09:00 ET Signant Health Global eCOA Library Surpasses 9,000 Translations, Accelerating Global Study Startup
sponsors can plan around with confidence."The library spans a wide range of therapeutic areas, with particularly strong coverage in oncology, CNS, and dermatology. Coverage expands continuously as validated translations from new studies are added to the library.For more information about
More news about: Signant Health
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
CNS Spectrums.
More news about: Neurocrine Biosciences, Inc.
Aug 12, 2026, 01:21 ET Gen Z Visitors Explore Guizhou's Path to Global Markets
GUIYANG, China, Aug. 12, 2026 /PRNewswire/ -- A news report from CNS: In the mountains of southwest China's Guizhou Province, industries once unlikely to be associated with a remote inland
More news about: CNS
Aug 11, 2026, 10:30 ET Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and other disease indications. Graviton has developed a portfolio of selective ROCK2 inhibitors among other safe, innovative, and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. GV101 is in clinical studies,
More news about: Graviton Bioscience Corporation
Aug 11, 2026, 07:50 ET SLENYTO® (melatonin extended-release tablets) is now available in Canada as a prescription treatment for insomnia in children and adolescents with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS).
neurodevelopmental disorders. Through pioneering scientific research and CNS focused drug development as well as collaboration with public and private healthcare organizations, Neurim Pharmaceuticals is realizing its vision, addressing key unmet needs in CNS disease management, improving the quality of life of patients
More news about: Kye Pharmaceuticals Inc.
Aug 10, 2026, 16:18 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for July 2026
NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $102.5 billion at July 31, 2026, an increase of $2.4 billion from assets under management of $100.1
More news about: Cohen & Steers, Inc.
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
over any consecutive six-month treatment period (n>100), while opakalim continued to demonstrate a favorable safety profile with a low incidence of CNS adverse events. Topline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026.Continued
More news about: Biohaven Ltd.
Aug 06, 2026, 11:33 ET CureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven Innovation
growing C9orf72 biorepository. These cells will be reprogrammed into induced pluripotent stem cells (iPSCs) and differentiated into disease-relevant CNS cell types—including motor neurons, astrocytes, and microglia—to provide researchers with standardized, commercially available models."BrainXell
More news about: BrainXell, Inc
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
AntagonistAXS-05 is an investigational oral therapy engineered with a multimodal mechanism of action to address disorders of the central nervous system (CNS). It combines dextromethorphan and bupropion in a proprietary formulation that is designed to optimize the pharmacological activity of dextromethorphan.
More news about: DelveInsight Business Research, LLP
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) Cancers. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1+ NSCLC patients with brain metastases.Safusidenib,
More news about: Nuvation Bio, Inc.
Aug 06, 2026, 07:30 ET Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Aug 06, 2026, 07:00 ET Corero Network Security Strengthens Position as Leader and Innovator in 2026 DDoS SPARK Matrix™
Marlborough, Massachusetts, USA, and Edinburgh, UK, Corero is headquartered in London and listed on the London Stock Exchange's AIM market (ticker: CNS) and the US OTCQX Market (OTCQX: DDOSF).
More news about: Corero Network Security
Aug 06, 2026, 04:34 ET Corero Network Security positioned as a Leader in the SPARK Matrix™: Distributed Denial of Service (DDoS) Mitigation, 2026 by QKS Group
Marlborough, Massachusetts, USA, and Edinburgh, UK, Corero is headquartered in London and listed on the London Stock Exchange's AIM market (LSE: CNS) and the US OTCQX Market (OTCQX: DDOSF). Media Contact: [email protected]
More news about: QKS Group
Aug 05, 2026, 09:00 ET Headlands Research Expands Pacific Northwest Presence with New Clinical Research Site in Bellingham, Washington
Led by a board-certified psychiatrist and 2025 APA Fellow, the site gives sponsors access to more than 615,000 participants in an untapped CNS research marketWEST PALM BEACH, Fla. and BELLINGHAM, Wash., Aug. 5, 2026
More news about: Headlands Research
Aug 05, 2026, 08:00 ET Foundation for Angelman Syndrome Therapeutics Announces Agreement with Apertura Gene Therapy for Access to Blood-Brain Barrier-Crossing Capsid
manufacturing by contract development and manufacturing organizations (CDMOs). TfR1 CapX is a proprietary, second-generation capsid that demonstrates superior CNS delivery compared to Apertura's first-generation capsid, BI-hTFR1. Research on the first-generation BI-hTFR1 capsid was published in
More news about: Apertura Gene Therapy
Aug 04, 2026, 09:00 ET Corero Network Security Technology Powers TierPoint's New Adapt DDoS Protection
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service ("DDoS") protection specialists and champion of adaptive, real-time service availability, today announced
More news about: Corero Network Security
Aug 04, 2026, 09:00 ET PM360 Announces 2026 Lifetime Achievement Award Honoree, CMO of the Year, and Brand Champions
Brand Communications, LIB Therapeutics, Inc.CardiopulmonaryMichelle Gallant, Senior Director of U.S. Marketing, LiquidiaCNS Patti Russo, Worldwide VP, Immunology Global Commercial Strategy, Bristol Myers SquibbDermatologyBrittany Mathes, Senior
More news about: PM360
Aug 04, 2026, 08:21 ET FDA Grants Fast Track Designation to Xellsmart Off-The-Shelf Cell Therapy for Parkinson's Disease
Parkinson's patients globally.About XellSmartXellSmart is a clinical-stage, regenerative medicine company focusing on treating CNS diseases with clinical-grade, allogeneic, off-the-shelf, iPSC-derived cell therapies.Founded by Dr. Xiang Li following his return to China, XellSmart
More news about: XellSmart Biopharmaceutical Co., Ltd.
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
Aug 03, 2026, 21:12 ET China-ASEAN Alliance for Lifelong Learning Resmi Diluncurkan
GUIYANG, Tiongkok, 4 Agustus 2026 /PRNewswire/ -- Artikel berita dari CNS: China-ASEAN Alliance for Lifelong Learning resmi diluncurkan dalam edisi perdana International Forum on Digital Empowerment for Lifelong Learning.
More news about: CNS
Aug 03, 2026, 18:26 ET CNS: Lulusan Vietnam Bangun Bisnis Lintasnegara di Guizhou Berbekal Pengalaman Studi di Tiongkok
GUIYANG, Tiongkok, 3 Agustus 2026 /PRNewswire/ -- Artikel berita dari CNS:Beberapa pekan setelah meraih gelar magister dari Guizhou Normal University, warga negara Vietnam Tran Le Huong Giang mendirikan perusahaan di Guian New Area, Guiyang. Perusahaan yang resmi terdaftar pada awal
More news about: CNS
Aug 03, 2026, 10:31 ET Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
Development: Pharmaceutical companies are increasingly focusing on novel mechanisms of action, including selective serotonin receptor modulation and other CNS-targeted approaches. These innovations are expanding the treatment landscape and improving therapeutic outcomes.Growing Clinical Research
More news about: DelveInsight Business Research, LLP
Aug 03, 2026, 10:27 ET CNS: Cựu du học sinh Việt Nam biến hành trình học tập tại Trung Quốc thành sự nghiệp kinh doanh xuyên biên giới ở Quý Châu
QUÝ DƯƠNG, Trung Quốc, ngày 3 tháng 8 năm 2026 /PRNewswire/ -- Bản tin từ CNS:Chỉ vài tuần sau khi nhận bằng thạc sĩ tại Đại học Sư phạm Quý Châu, công dân Việt Nam Trần Lê Hương Giang đã thành lập công ty riêng tại Khu mới Quý An, thành phố Quý Dương. Được đăng
More news about: CNS
Aug 02, 2026, 22:40 ET China-ASEAN Education Cooperation Week 2026 Unveils Major Initiatives
GUIYANG, China, Aug. 2, 2026 /PRNewswire/ -- A news report from CNS: The 2026 China-ASEAN Education Cooperation Week (CAECW) marked a significant milestone on Wednesday, unveiling a comprehensive portfolio of strategic
More news about: CNS